Yi Ning

发表

Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs.

Huibin Zhang, Jinpei Zhou, Jian Ding, 2020, ACS medicinal chemistry letters.

Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.

Huibin Zhang, Jinpei Zhou, Jian Ding, 2020, European journal of medicinal chemistry.

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

Yi Chen, Jian Ding, Lin-jiang Tong, 2022, Frontiers in Pharmacology.

Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo

K. Yu, Yi Chen, Jian Ding, 2023, Journal of Cancer.

PCDH20 inhibits esophageal squamous cell carcinoma proliferation and migration by suppression of the mitogen-activated protein kinase 9/AKT/β-catenin pathway

T. Xiang, Lin Ye, Jing Ran, 2022, Frontiers in Oncology.

LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo

Kai Yu, Yi Chen, Jian Ding, 2021, Cancer science.

Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors.

Huibin Zhang, Jinpei Zhou, Jian Ding, 2021, Bioorganic & medicinal chemistry.

Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma.

Huibin Zhang, Jinpei Zhou, W. Duan, 2023, European journal of medicinal chemistry.

A Novel IRAK4 Inhibitor DW18134 Ameliorates Peritonitis and Inflammatory Bowel Disease

Yun Chen, Yi Ning, Zhengsheng Zhan, 2024, Molecules.

ASK120067 (limertinib) exerts pre-clinical anti-tumor activity by inhibiting EGFR exon20 insertion

Yi Chen, Jian Ding, Lin-jiang Tong, 2022, Frontiers in Drug Discovery.

Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation

Lin-jiang Tong, Huancheng Zhou, Gang Bai, 2024, Signal transduction and targeted therapy.